E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
High-risk smouldering multiple myeloma or "SLiM CRAB" positive early multiple myeloma |
|
E.1.1.1 | Medical condition in easily understood language |
High-risk smouldering multiple myeloma is a precursor and "SLiM CRAB" positive early multiple myeloma is an early phase of multiple myeloma, a is a cancer of plasma cells, a type of white blood cell. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10067386 |
E.1.2 | Term | Multiple myeloma transformation |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10075894 |
E.1.2 | Term | Smoldering myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Effectiveness of denosumab in delaying transformation to symptomatic, active MM or progression of disease. |
|
E.2.2 | Secondary objectives of the trial |
- Effectiveness of denosumab in reduction of percentage of patients developing serological progression within 3 years - Effectiveness of denosumab in reduction of progression rate in high risk MM patients - Effectiveness of denosumab in reduction of progression rate in “SLiM CRAB” myeloma patients - Effectiveness of denosumab in reduction of skeletal-related events (SRE) defining progression to active MM - Effectiveness of denosumab in delaying time to skeletal-related events - Effectiveness of denosumab in delaying time to symptomatic skeletal-related events - Effectiveness of denosumab in delaying time to first anti-myeloma treatment - Influence of denosumab regarding overall survival of patients with high-risk SMM and early ‘SLiM CRAB’ positive MM |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age ≥ 18 years • Able to provide written informed consent in accordance with federal, local, and institutional guidelines • Must meet criteria of high risk smoldering MM or early "SLiM CRAB" MM based on the criteria described below: o High-risk SMM is defined here according to the revised Mayo Clinical algorithm (2 out of 3 criteria must be fulfilled): • Bone marrow clonal plasma cells >20% • Serum M protein >2.0g/dL • Serum free light chain ratio >20 measured with “Binding site Kit” o Early ‘SLiM CRAB’ multiple myeloma (3) Patients must present with only one of the following features • Bone marrow clonal plasma cells ≥ 60%, or • Serum FLC ratio ≥ 100 (k-LC leading) or ≤ 0.01 (l-LC leading), measured with “Binding site Kit”, or • >1 Focal bone lesion of ≥5mm (not associated with osteolysis, detected by PET-CT or whole-body low-dose CT (WBLDCT)) • Time from diagnosis of high risk SMM or SLIM CRAB positive, early MM to study enrollment: <5 years |
|
E.4 | Principal exclusion criteria |
• ECOG >3 • Active, symptomatic MM (fulfilling CRAB-criteria) • Non secretory MM, extramedullary plasmacytoma, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) • MGUS • Hypocalcemia (can be corrected by drug intervention before start of treatment) • Second malignancy within the past 5 years except: o Adequately treated basal cell or squamous cell skin cancer o Carcinoma in situ of the cervix o Prostate cancer Gleason score ≤ 6 with stable prostate-specific antigen (PSA over 12 months) o Ductal breast carcinoma in situ with full surgical resection (i.e., negative margins) o Treated medullary or papillary thyroid cancer o Similar condition with an expectation of > 95% five-year disease-free survival • Active infection within the 14 days prior to randomization requiring systemic antibiotics and/or antiviral therapy • Known human immunodeficiency virus (HIV) seropositivity or active hepatitis C or hepatitis B infection (subjects with past hepatitis B virus [HBV] infection or resolved HBV infection defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti HBc] antibody test are eligible; subjects positive for hepatitis C virus [HCV] antibody are eligible only if polymerase chain reaction [PCR] is negative for HCV RNA.) • Participation in another interventional study within the 28 days prior to randomization • Any other clinically significant medical disease or social condition that, in the investigator’s opinion, may interfere with protocol adherence or a subject’s ability to give informed consent, be compliant with study procedures, or provide accurate information. • Prior administration of denosumab • Prior exposure to any experimental or approved anti-myeloma agent • Use of oral bisphosphonates with a cumulative exposure of more than 1 year (wash out period for allowed bisphosphonate exposure 1 month) • More than 1 previous dose of IV bisphosphonate administration or teriparatide (wash out period for allowed bisphosphonate exposure 1 month) • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw • Active dental or jaw condition which requires oral surgery, including tooth extraction • Subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment • Female subject of child bearing potential is not willing to use, in combination with her partner, a highly effective and in addition an effective contraception during treatment and for 5 months after the end of treatment • Known sensitivity to denosumab (including all components of the formulation) or any of the products to be administered during the study (e.g. mammalian derived products, calcium, or vitamin D) • Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication). • Subject will not be available for follow-up assessment |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time from randomization to transformation to symptomatic, active MM (defined as progression to active multiple myeloma according to IMWG diagnosis criteria 2014) or progression of disease according to IMWG response criteria 2016. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Monthly during the first 6 months and 3-monthly until a maximum of 3 years. |
|
E.5.2 | Secondary end point(s) |
1. Percentage of patients transforming to CRAB positive multiple myeloma and/or developing serological progression (as defined by IMWG criteria 2016 for MM) within three years. 2. Percentage of high risk SMM patients progressed to active, symptomatic MM within 3 years. 3. Percentage of “SLiM”- part of “SLiM CRAB” criteria fulfilling patients at inclusion progressing to CRAB-positive MM within three years 4. Incidence of bone lesions as MM defining events 5. Time to first skeletal-related event 6. Time to symptomatic skeletal-related event 7. Time to first anti-myeloma treatment 8. Overall survival
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Endpoints 1-3: at baseline monthly during first 6 months and 3-monthly until a maximum of 3 years
Endpoints 4-6: at baseline and every 6 months thereafter until a maximum of 3 years
Endpoints 7-8: from randomizaton until end of study (12 months after end of treatment of last patient) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 6 |